Determination of the Prevalence of Microsatellite Instability, BRAF and KRAS/NRAS Mutation Status in Patients with Colorectal Cancer in Slovakia

被引：0
|
作者：
Rendek, Tomas [1 ]
Saade, Rami [2 ]
Pos, Ondrej [3 ,4 ]
Kolnikova, Georgina [5 ]
Urbanova, Monika [5 ]
Budis, Jaroslav [3 ,4 ]
Mihok, Luboslav [6 ]
Tomas, Miroslav [7 ]
Szemes, Tomas [3 ,4 ]
Repiska, Vanda [1 ]
机构：
[1] Comenius Univ, Inst Med Biol Genet & Clin Genet, Fac Med, Bratislava 81108, Slovakia
[2] Comenius Univ, Fac Med, Dept Gynaecol & Obstet 2, Bratislava 81108, Slovakia
[3] Geneton Ltd, Bratislava 84104, Slovakia
[4] Comenius Univ, Sci Pk, Bratislava 84104, Slovakia
[5] NCI, Dept Pathol Anat, Bratislava 83310, Slovakia
[6] NCI, Dept Med Genet, Bratislava 83310, Slovakia
[7] Slovak Med Univ, NCI, Surg Oncol Clin, Bratislava 83310, Slovakia
来源：
CANCERS | 2024年 / 16卷 / 06期
关键词：
microsatellite instability; colorectal cancer; BRAF; KRAS; NRAS mutations; RAS MUTATIONS; KRAS; BENEFIT;
D O I：
10.3390/cancers16061128
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Slovakia has one of the highest rates of colorectal cancer among the developed countries, ranking as the second highest in the incidence of this disease for men worldwide. Despite the significant burden on both quality of life and the healthcare system this disease imposes, data on molecular analysis of biomarkers in CRC-diagnosed patients is scarce. In our study, we analyzed confirmed CRC patients from the database of the National Cancer Institute (NCI) and evaluated the presence of 4 biomarkers in tumor tissues. Altogether, 83 FFPE tumor tissues from CRC patients listed in the NCI database were analyzed for microsatellite instability status, presence of BRAF and KRAS/NRAS mutations, and neoplastic cell percentage in tissue samples. We identified 4 MSI-high samples, 39 KRAS/NRAS mutations, and 5 BRAF p.V600E mutations, with one case of coexistence of all three markers in a single tumor sample. We also evaluated possible relationships between biomarkers, their coexistence, and the age and sex of the studied population.
引用
收藏
页数：10
相关论文
共 50 条
  • [31] First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients
    Vladimir M. Moiseyenko
    Fedor V. Moiseyenko
    Grigoriy A. Yanus
    Ekatherina Sh. Kuligina
    Anna P. Sokolenko
    Ilya V. Bizin
    Alexey A. Kudriavtsev
    Svetlana N. Aleksakhina
    Nikita M. Volkov
    Vyacheslav A. Chubenko
    Kseniya S. Kozyreva
    Mikhail M. Kramchaninov
    Alexandr S. Zhuravlev
    Kseniya V. Shelekhova
    Denis V. Pashkov
    Alexandr O. Ivantsov
    Aigul R. Venina
    Tatyana N. Sokolova
    Elena V. Preobrazhenskaya
    Natalia V. Mitiushkina
    Alexandr V. Togo
    Aglaya G. Iyevleva
    Evgeny N. Imyanitov
    Clinical Drug Investigation, 2018, 38 : 553 - 562
  • [32] Re: Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication
    Rosty, Christophe
    Wiliamson, Elizabeth J.
    Clendening, Mark
    Walters, Rhianon J.
    Walsh, Michael D.
    Win, Aung K.
    Jenkins, Mark A.
    Hoper, John L.
    Winship, Ingrid
    Southey, Melisa C.
    Giles, Graham G.
    English, Dalas R.
    Buchanan, Daniel D.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (08):
  • [33] KRAS, NRAS and BRAF Mutation Prevalence and its Clinicopathological Association in Colorectal Carcinoma with Emphasis on Tumor Budding
    Ghafoor, Mariam
    Ajmal, Namra
    Wang, Zixuan
    Bashir, Babar
    Lin, Daniel
    Peiper, Stephen
    Jiang, Wei
    Ambelil, Manju
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 458 - 459
  • [34] Assessment of BRAF, NRAS, KRAS and EGFR mutation status in thyroid nodules
    Novy, M.
    Hofner, M.
    Oberkanins, C.
    Vierlinger, K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S97 - S97
  • [35] KRAS, NRAS and BRAF Mutation Prevalence and its Clinicopathological Association in Colorectal Carcinoma with Emphasis on Tumor Budding
    Ghafoor, Mariam
    Ajmal, Namra
    Wang, Zixuan
    Bashir, Babar
    Lin, Daniel
    Peiper, Stephen
    Jiang, Wei
    Ambelil, Manju
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 458 - 459
  • [36] KRAS, NRAS and BRAF Mutation Prevalence and its Clinicopathological Association in Colorectal Carcinoma with Emphasis on Tumor Budding
    Ghafoor, Mariam
    Ajmal, Namra
    Wang, Zixuan
    Bashir, Babar
    Lin, Daniel
    Peiper, Stephen
    Jiang, Wei
    Ambelil, Manju
    MODERN PATHOLOGY, 2022, 35 : 458 - 459
  • [37] KRAS, NRAS, and BRAF mutation prevalence, clinicopathological association, and their application in a predictive model in Mexican patients with metastatic colorectal cancer: A retrospective cohort study
    Sanchez-Ibarra, Hector Eduardo
    Jiang, Xianli
    Gallegos-Gonzalez, Elena Yareli
    Cavazos-Gonzalez, Adriana Carolina
    Chen, Yenho
    Morcos, Faruck
    Barrera-Saldana, Hugo Alberto
    PLOS ONE, 2020, 15 (07):
  • [38] Metabolic factors and the risk of colorectal cancer by KRAS and BRAF mutation status
    Myte, Robin
    Gylling, Bjorn
    Haggstrom, Jenny
    Haggstrom, Christel
    Zingmark, Carl
    Burstrom, Anna Lofgren
    Palmqvist, Richard
    Van Guelpen, Bethany
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (02) : 327 - 337
  • [39] KRAS, NRAS, and BRAF Mutation Pattern in Metastatic Colorectal Cancer: A Study from Northwest Iran
    Dolatkhah, Roya
    Dastgiri, Saeed
    Kermani, Iraj Asvadi
    Ziaei, Jamal Eivazi
    Nikanfar, Alireza
    Sanaat, Zohreh
    Sadat, Amir Taher Eftekhar
    Somi, Mohammad Hossein
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2019, 13 (08) : EC9 - EC13
  • [40] KRAS Mutation in Gastric Cancer and Prognostication Associated with Microsatellite Instability Status
    Polom, Karol
    Das, Kakoli
    Marrelli, Daniele
    Roviello, Giandomenico
    Pascale, Valeria
    Voglino, Costantino
    Rho, Henry
    Tan, Patrick
    Roviello, Franco
    PATHOLOGY & ONCOLOGY RESEARCH, 2019, 25 (01) : 333 - 340
12345